Skip to main content
Erschienen in: Nuclear Medicine and Molecular Imaging 4/2017

10.04.2017 | Original Article

Relationship Between Dual Time Point FDG PET/CT and Clinical Prognostic Indexes in Patients with High Grade Lymphoma: a Pilot Study

verfasst von: Do Hyoung Lim, Jai Hyuen Lee

Erschienen in: Nuclear Medicine and Molecular Imaging | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study investigated the correlative relationship between metabolic parameters estimated from dual time point 2-deoxy-2-[18F] fluoro-D-glucose (18F-FDG) positron emission tomography/computerized tomography (PET/CT) and the clinical tools predicting the outcome of a lymphoma. We also measured metabolic and volumetric alterations between early and delayed 18F-FDG PET/CT in patients with high grade lymphoma (HGL).

Methods

The samples were 122 lymph nodes and extralymphatic lesions from 26 patients diagnosed with HGL. All patients were applied to the International Prognostic Index (IPI), Ann Arbor stage, and revised IPI as clinical prognostic parameters. 18F-FDG dual time point PET/CT (DTPFP) consisted of an early scan 1 h after 18F-FDG injection and a delayed scan 2 h after the early scan. Based on an analysis of DTPFP, we estimated the standardized uptake value (SUV) of tumors from the early and delayed scans, retention index (RI) representing the percentage change between early and delayed SUV, and metabolic volume different index (MVDI) calculated using metabolic tumor volumes (MTV).

Results

RImax showed a multiple positive correlative relationship with stage and IPI in lesion-by-lesion analysis (p < 0.01). In the case of IPI, the high risk group exhibited higher RImax than the low risk group (p = 0.004). In the case of revised IPI, the RImax of the low risk group were significantly lower than the intermediate and high risk groups, respectively (p < 0.01). The MVDIs of the best outcome group were decreased in comparison to the moderate outcome group (p = 0.029). There was a significant negative correlative relationship between RImax and MVDI, and the inclinations for decreased MVDIs were slightly associated with increased RIs.

Conclusions

RImax extracted from DTPFP had a significant relationship to extranodal involvement, staging, IPI, and revised IPI. MVDI showed significant negative correlation with RImax. Further large scale studies are warranted to support and extend these preliminary results.
Literatur
2.
Zurück zum Zitat Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. CA Cancer J Clin. 2013;63:11–30.CrossRefPubMed Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. CA Cancer J Clin. 2013;63:11–30.CrossRefPubMed
3.
Zurück zum Zitat Wilder RB, Rodriguez MA, Medeiros LJ, Tucker SL, Ha CS, Romaguera JE, et al. International prognostic index‐based outcomes for diffuse large B‐cell lymphomas. Cancer. 2002;94:3083–88.CrossRefPubMed Wilder RB, Rodriguez MA, Medeiros LJ, Tucker SL, Ha CS, Romaguera JE, et al. International prognostic index‐based outcomes for diffuse large B‐cell lymphomas. Cancer. 2002;94:3083–88.CrossRefPubMed
4.
Zurück zum Zitat Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.CrossRefPubMed Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.CrossRefPubMed
5.
Zurück zum Zitat Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837–42.CrossRefPubMedPubMedCentral Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837–42.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.CrossRefPubMed Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.CrossRefPubMed
7.
Zurück zum Zitat Salles G, de Jong D, Xie W, Rosenwald A, Chhanabhai M, Gaulard P, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood. 2011;117:7070–78.CrossRefPubMed Salles G, de Jong D, Xie W, Rosenwald A, Chhanabhai M, Gaulard P, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood. 2011;117:7070–78.CrossRefPubMed
8.
Zurück zum Zitat Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857–61.CrossRefPubMed Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857–61.CrossRefPubMed
9.
Zurück zum Zitat Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:2373–80.CrossRefPubMed Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:2373–80.CrossRefPubMed
10.
Zurück zum Zitat Matthies A, Hickeson M, Cuchiara A, Alavi A. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med. 2002;43:871–5.PubMed Matthies A, Hickeson M, Cuchiara A, Alavi A. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med. 2002;43:871–5.PubMed
11.
Zurück zum Zitat Uesaka D, Demura Y, Ishizaki T, Ameshima S, Miyamori I, Sasaki M, et al. Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer. J Nucl Med. 2008;49:1606–12.CrossRefPubMed Uesaka D, Demura Y, Ishizaki T, Ameshima S, Miyamori I, Sasaki M, et al. Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer. J Nucl Med. 2008;49:1606–12.CrossRefPubMed
12.
Zurück zum Zitat Kumar R, Loving VA, Chauhan A, Zhuang H, Mitchell S, Alavi A. Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. J Nucl Med. 2005;46:1819–24.PubMed Kumar R, Loving VA, Chauhan A, Zhuang H, Mitchell S, Alavi A. Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. J Nucl Med. 2005;46:1819–24.PubMed
13.
Zurück zum Zitat Sanghera B, Wong WL, Lodge MA, Hain S, Stott D, Lowe J, et al. Potential novel application of dual time point SUV measurements as a predictor of survival in head and neck cancer. Nucl Med Commun. 2005;26:861–7.CrossRefPubMed Sanghera B, Wong WL, Lodge MA, Hain S, Stott D, Lowe J, et al. Potential novel application of dual time point SUV measurements as a predictor of survival in head and neck cancer. Nucl Med Commun. 2005;26:861–7.CrossRefPubMed
14.
Zurück zum Zitat Nakayama M, Okizaki A, Ishitoya S, Sakaguchi M, Sato J, Aburano T. Dual-time-point F-18 FDG PET/CT imaging for differentiating the lymph nodes between malignant lymphoma and benign lesions. Ann Nucl Med. 2013;27:163–9.CrossRefPubMed Nakayama M, Okizaki A, Ishitoya S, Sakaguchi M, Sato J, Aburano T. Dual-time-point F-18 FDG PET/CT imaging for differentiating the lymph nodes between malignant lymphoma and benign lesions. Ann Nucl Med. 2013;27:163–9.CrossRefPubMed
15.
Zurück zum Zitat Shinya T, Fujii S, Asakura S, Taniguchi T, Yoshio K, Alafate A, et al. Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma. Ann Nucl Med. 2012;26:616–21.CrossRefPubMed Shinya T, Fujii S, Asakura S, Taniguchi T, Yoshio K, Alafate A, et al. Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma. Ann Nucl Med. 2012;26:616–21.CrossRefPubMed
16.
Zurück zum Zitat Orlhac F, Soussan M, Maisonobe JA, Garcia CA, Vanderlinden B, Buvat I. Tumor texture analysis in 18F-FDG PET: relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis. J Nucl Med. 2014;55:414–22.CrossRefPubMed Orlhac F, Soussan M, Maisonobe JA, Garcia CA, Vanderlinden B, Buvat I. Tumor texture analysis in 18F-FDG PET: relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis. J Nucl Med. 2014;55:414–22.CrossRefPubMed
17.
Zurück zum Zitat Hoekstra OS, Ossenkoppele GJ, Golding R, Van Lingen A, Visser G, Teule G, et al. Early treatment response in malignant lymphoma determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med. 1993;34:1706.PubMed Hoekstra OS, Ossenkoppele GJ, Golding R, Van Lingen A, Visser G, Teule G, et al. Early treatment response in malignant lymphoma determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med. 1993;34:1706.PubMed
18.
Zurück zum Zitat Surbone A, Longo DL, DeVita Jr VT, Ihde DC, Duffey PL, Jaffe ES, et al. Residual abdominal masses in aggressive non-Hodgkin’s lymphoma after combination chemotherapy: significance and management. J Clin Oncol. 1988;6:1832–37.CrossRefPubMed Surbone A, Longo DL, DeVita Jr VT, Ihde DC, Duffey PL, Jaffe ES, et al. Residual abdominal masses in aggressive non-Hodgkin’s lymphoma after combination chemotherapy: significance and management. J Clin Oncol. 1988;6:1832–37.CrossRefPubMed
19.
Zurück zum Zitat Bodet-Milin C, Eugène T, Gastinne T, Bailly C, Le Gouill S, Dupas B, et al. The role of FDG-PET scanning in assessing lymphoma in 2012. Diag int Imaging. 2013;94:158–68.CrossRef Bodet-Milin C, Eugène T, Gastinne T, Bailly C, Le Gouill S, Dupas B, et al. The role of FDG-PET scanning in assessing lymphoma in 2012. Diag int Imaging. 2013;94:158–68.CrossRef
20.
Zurück zum Zitat Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106:1376–81.CrossRefPubMed Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106:1376–81.CrossRefPubMed
21.
Zurück zum Zitat Weber WA. 18F-FDG PET in non-Hodgkin’s lymphoma: qualitative or quantitative? J Nucl Med. 2007;48:1580–82.CrossRefPubMed Weber WA. 18F-FDG PET in non-Hodgkin’s lymphoma: qualitative or quantitative? J Nucl Med. 2007;48:1580–82.CrossRefPubMed
22.
Zurück zum Zitat Mikhaeel NG, Hutchings M, Fields PA, O’Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005;16:1514–23.CrossRefPubMed Mikhaeel NG, Hutchings M, Fields PA, O’Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005;16:1514–23.CrossRefPubMed
23.
Zurück zum Zitat Chan W, Ramsay SC, Szeto ER, Freund J, Pohlen JM, Tarlinton LC, et al. Dual‐time‐point 18F‐FDG‐PET/CT imaging in the assessment of suspected malignancy. J Med imaging Radiation Oncol. 2011;55:379–90.CrossRef Chan W, Ramsay SC, Szeto ER, Freund J, Pohlen JM, Tarlinton LC, et al. Dual‐time‐point 18F‐FDG‐PET/CT imaging in the assessment of suspected malignancy. J Med imaging Radiation Oncol. 2011;55:379–90.CrossRef
24.
Zurück zum Zitat Xiu Y, Bhutani C, Dhurairaj T, Yu JQ, Dadparvar S, Reddy S, et al. Dual-time point FDG PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity. Clin Nucl Med. 2007;32:101–5.CrossRefPubMed Xiu Y, Bhutani C, Dhurairaj T, Yu JQ, Dadparvar S, Reddy S, et al. Dual-time point FDG PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity. Clin Nucl Med. 2007;32:101–5.CrossRefPubMed
25.
Zurück zum Zitat Zytoon A, Murakami K, El-Kholy M, El-Shorbagy E. Dual time point FDG-PET/CT imaging… Potential tool for diagnosis of breast cancer. Clin Radiol. 2008;63:1213–27.CrossRefPubMed Zytoon A, Murakami K, El-Kholy M, El-Shorbagy E. Dual time point FDG-PET/CT imaging… Potential tool for diagnosis of breast cancer. Clin Radiol. 2008;63:1213–27.CrossRefPubMed
26.
Zurück zum Zitat Fuster D, Lafuente S, Setoain X, Navales I, Perissinotti A, Pavia J, et al. Dual-time point images of the liver with 18 F-FDG PET/CT in suspected recurrence from colorectal cancer. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition). 2012;31:111–6.CrossRef Fuster D, Lafuente S, Setoain X, Navales I, Perissinotti A, Pavia J, et al. Dual-time point images of the liver with 18 F-FDG PET/CT in suspected recurrence from colorectal cancer. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition). 2012;31:111–6.CrossRef
27.
Zurück zum Zitat Higashi T, Saga T, Nakamoto Y, Ishimori T, Mamede MH, Wada M, et al. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002;43:173–80.PubMed Higashi T, Saga T, Nakamoto Y, Ishimori T, Mamede MH, Wada M, et al. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002;43:173–80.PubMed
28.
Zurück zum Zitat Ma SY, See LC, Lai CH, Chou HH, Tsai CS, Ng KK, et al. Delayed (18)F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients. J Nucl Med. 2003;44:1775–83.PubMed Ma SY, See LC, Lai CH, Chou HH, Tsai CS, Ng KK, et al. Delayed (18)F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients. J Nucl Med. 2003;44:1775–83.PubMed
29.
Zurück zum Zitat Costantini DL, Vali R, Chan J, McQuattie S, Charron M. Dual–time-point FDG PET/CT for the evaluation of pediatric tumors. Am J Roentgenol. 2013;200:408–13.CrossRef Costantini DL, Vali R, Chan J, McQuattie S, Charron M. Dual–time-point FDG PET/CT for the evaluation of pediatric tumors. Am J Roentgenol. 2013;200:408–13.CrossRef
30.
Zurück zum Zitat Kim DH, Jung JH, Son SH, Kim CY, Hong CM, Oh JR, et al. Prognostic significance of intratumoral metabolic heterogeneity on 18F-FDG PET/CT in pathological N0 non-small cell lung cancer. Clin Nucl Med. 2015;40:708–14.CrossRefPubMed Kim DH, Jung JH, Son SH, Kim CY, Hong CM, Oh JR, et al. Prognostic significance of intratumoral metabolic heterogeneity on 18F-FDG PET/CT in pathological N0 non-small cell lung cancer. Clin Nucl Med. 2015;40:708–14.CrossRefPubMed
31.
Zurück zum Zitat Tixier F, Le Rest CC, Hatt M, Albarghach N, Pradier O, Metges JP, et al. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med. 2011;52:369–78.CrossRefPubMedPubMedCentral Tixier F, Le Rest CC, Hatt M, Albarghach N, Pradier O, Metges JP, et al. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med. 2011;52:369–78.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Kitao T, Hirata K, Shima K, Tamaki N. Influence of uptake time on metabolic tumor volume (MTV) and total lesion glycolysis (TLG) on FDG PET in non-small cell lung cancer (NSCLC). Soc Nuclear Med. 2014;55 Suppl 1:1597. Kitao T, Hirata K, Shima K, Tamaki N. Influence of uptake time on metabolic tumor volume (MTV) and total lesion glycolysis (TLG) on FDG PET in non-small cell lung cancer (NSCLC). Soc Nuclear Med. 2014;55 Suppl 1:1597.
33.
Zurück zum Zitat Liu H, Chen P, Wroblewski K, Hou P, Zhang CP, Jiang Y, et al. Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake times. Nucl Med Commun. 2016;37:50–6.PubMedPubMedCentral Liu H, Chen P, Wroblewski K, Hou P, Zhang CP, Jiang Y, et al. Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake times. Nucl Med Commun. 2016;37:50–6.PubMedPubMedCentral
Metadaten
Titel
Relationship Between Dual Time Point FDG PET/CT and Clinical Prognostic Indexes in Patients with High Grade Lymphoma: a Pilot Study
verfasst von
Do Hyoung Lim
Jai Hyuen Lee
Publikationsdatum
10.04.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Nuclear Medicine and Molecular Imaging / Ausgabe 4/2017
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-017-0480-y

Weitere Artikel der Ausgabe 4/2017

Nuclear Medicine and Molecular Imaging 4/2017 Zur Ausgabe